Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Eija Kellokoski"'
Autor:
Maarit Jokela, Eija Kellokoski, Anne Kunnari, Y. Antero Kesäniemi, Sanna Mäkelä, Sohvi Hörkkö
Publikováno v:
Metabolism. 58:1572-1580
Emerging evidence indicates the potential involvement of ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, in low-grade inflammatory diseases such as obesity and atherosclerosis. The goal of the present study was to use cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1759518c8ca1b7d7d7d7a52ba8a5ae86
https://doi.org/10.1016/j.metabol.2009.05.009
https://doi.org/10.1016/j.metabol.2009.05.009
Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males
Autor:
Olavi Ukkola, Heikki Kauma, Sohvi Hörkkö, Seppo M. Pöykkö, Y. A. Kesäniemi, Markku Päivänsalo, Eija Kellokoski
Publikováno v:
Journal of Internal Medicine. 260:43-52
Background. Ghrelin, a peptide hormone from stomach, stimulates food intake and decreases fat utilization. Ghrelin binds to growth hormone secretagogue receptor (GHSR). GHSR density has been shown to be upregulated in atherosclerotic lesions, but the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eabf723b3c93811743cfab472016161
https://doi.org/10.1111/j.1365-2796.2006.01661.x
https://doi.org/10.1111/j.1365-2796.2006.01661.x
Publikováno v:
Diabetologia. 48:309-316
Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown eith
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8548538858cd929837e9d6510ca4460
https://doi.org/10.1007/s00125-004-1635-9
https://doi.org/10.1007/s00125-004-1635-9
Autor:
Y. Antero Kesäniemi, Raisa Serpi, Outi Kummu, Petri Lehenkari, Sohvi Hörkkö, Eija Kellokoski, Olavi Ukkola
Publikováno v:
Peptides. 30(12)
Ghrelin is a novel peptide hormone having growth hormone releasing activity and many endocrine and metabolic functions. In rats and pigs, ghrelin immunizations have recently been shown to induce an antibody response against ghrelin simultaneously wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1bcb499a11bb683e2a5e7a7c1b0e950
https://pubmed.ncbi.nlm.nih.gov/19751783
https://pubmed.ncbi.nlm.nih.gov/19751783
Autor:
Seppo M. Pöykkö, Eija Kellokoski, Y. Antero Kesäniemi, Anna Karjalainen, Olavi Ukkola, Jorma Heikkinen, Sohvi Hörkkö
Publikováno v:
The Journal of clinical endocrinology and metabolism. 90(5)
Ghrelin is a novel peptide hormone that has GH releasing activity and also other endocrine and metabolic functions. The purpose of this study was to investigate the effects of estrogen replacement therapy on plasma active ghrelin levels in 64 hystere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::858fef634d4f842b46d1fb8fe6c8c00c
https://pubmed.ncbi.nlm.nih.gov/15872336
https://pubmed.ncbi.nlm.nih.gov/15872336
Autor:
Seppo M. Pöykkö, Eija Kellokoski, Heikki Kauma, Olavi Ukkola, Sohvi Hörkkö, Y. Antero Kesäniemi
Publikováno v:
University of Helsinki
Experimental studies have suggested that ghrelin plays a role in glucose homeostasis and in the regulation of blood pressure (BP). We therefore assessed the hypothesis that a low ghrelin concentration may be a risk factor for type 2 diabetes and hype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73760047b1ccc6dd141cd8651773fb9c
https://pubmed.ncbi.nlm.nih.gov/14514639
https://pubmed.ncbi.nlm.nih.gov/14514639
Publikováno v:
Atherosclerosis Supplements. 8:188
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c90ab2b37356499df7fe86ef11888001
https://doi.org/10.1016/s1567-5688(07)71713-0
https://doi.org/10.1016/s1567-5688(07)71713-0